Drug-induced hypersensitivity syndrome after bortezomib treatment for refractory multiple myeloma.
Norimichi
N
Hattori
Daisuke
D
Adachi
Hidetoshi
H
Nakashima
Bungo
B
Saito
Tsuyoshi
T
Nakamaki
Shigeru
S
Tomoyasu
D000212:Acyclovir / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000998:Antiviral Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D016572:Cyclosporine / Q000627:therapeutic use; D003907:Dexamethasone / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D005077:Exanthema Subitum / Q000188:drug therapy; D014645:Herpesvirus 3, Human; D015654:Herpesvirus 6, Human / Q000276:immunology / Q000502:physiology; D006801:Humans; D008297:Male; D008558:Melphalan / Q000627:therapeutic use; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011241:Prednisone / Q000627:therapeutic use; D011719:Pyrazines / Q000009:adverse effects*; D013577:Syndrome; D014775:Virus Activation / Q000276:immunology
D000970:Antineoplastic Agents; D000998:Antiviral Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib; D003907:Dexamethasone; D016572:Cyclosporine; D008558:Melphalan; D011241:Prednisone; D000212:Acyclovir